Ani Pharmaceuticals reported $34.27M in Cost of Sales for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cost Of Sales Change
Abbvie ABBV:US $ 4142M 121M
Aerie Pharmaceuticals AERI:US $ 3.74M 3.04M
Ani Pharmaceuticals ANIP:US $ 34.27M 373K
Aurora Cannabis Inc ACB:CN 103.36M 6.41M
Canopy Growth Corp WEED:CN C$ 111.51M 159.5M
Depomed DEPO:US $ 3.8M 1.1M
Eli Lilly And LLY:US $ 1430.5M 641.6M
Endo International Ordinary Shares ENDP:US $ 179.76M 42.71M
Heron Therapeutics HRTX:US $ 11.36M 0.41M
Hikma Pharmaceutical HIK:LN 590M 62M
Knight Therapeutics Inc GUD:CN C$ 31.33M 1.25M
Lannett LCI:US $ 75.28M 5.52M
Nektar Therapeutics NKTR:US $ 5.12M 0.2M
Novartis NVS:US $ 3749M 6M
Perrigo Ordinary Shares PRGO:US $ 736.7M 5.8M
Sun Pharmaceuticals SUNP:IN IR 29002M 3605.7M
Teva Pharmaceutical TEVA:IT 1.96B 99M
Teva Pharmaceutical Industries TEVA:US $ 1958M 99M